Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the EASL Congress 2026 (The ...
Bepirovirsen reduced posttreatment markers of hepatitis B infection at 72 weeks, with 20% of recipients achieving functional ...
-- VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported -- In the ...
New research suggests combining antiviral medicines with immune-based therapies could bring scientists closer to a functional ...
Twenty-four weeks of bepirovirsen achieves a functional cure in approximately one-fifth of patients with chronic hepatitis B.
Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming ...
Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of drugs, its luck ...
A multinational Hepatitis B and HIV Cure Consortium led by Johns Hopkins Medicine was recently established with the awarding of a five-year, $24 million grant from the National Institutes of Health's ...
Infant vaccination has reduced pediatric HBV infections by 99%, yet shared decision-making for the birth dose may precipitate irreversible coverage declines when recommendations shift from universal ...
Please provide your email address to receive an email when new articles are posted on . Global HBV incidence and mortality rates dropped from 1990 to 2021 among individuals aged 15 to 49 years.
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results